Neem's Hill AB (STO:NEEMS B) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. The kr78m market-cap company posted a loss in its most recent financial year of kr8.1m and a latest trailing-twelve-month loss of kr8.0m shrinking the gap between loss and breakeven. The most pressing concern for investors is Neem's Hill's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
According to some industry analysts covering Neem's Hill, breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of kr3.2m in 2027. So, the company is predicted to breakeven just over a year from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 163%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won’t go into details of Neem's Hill's upcoming projects, however, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.
See our latest analysis for Neem's Hill
Before we wrap up, there’s one aspect worth mentioning. Neem's Hill currently has no debt on its balance sheet, which is quite unusual for a cash-burning growth company, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
Next Steps:
There are key fundamentals of Neem's Hill which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Neem's Hill, take a look at Neem's Hill's company page on Simply Wall St. We've also compiled a list of essential factors you should further research:
- Historical Track Record: What has Neem's Hill's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Neem's Hill's board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.